MedPath

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Phase 2
Completed
Conditions
Haemostasis
Haemophilia A
Interventions
Registration Number
NCT03196297
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
36
Inclusion Criteria
  • Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial - Male patients aged 18 years or older at the time of signing informed consent, diagnosed with severe haemophilia A (FVIII activity below 1%), based on medical records or results at screening
Exclusion Criteria
  • Known or suspected hypersensitivity to trial product(s) or related products - Known inherited or acquired bleeding disorder other than haemophilia A - Presence of inhibitors (neutralising antibodies) to Factor VIII (equal to or above 0.6 Bethesda Units) at screening measured by the Nijmegen method

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ConcizumabTuroctocog alfaDaily administration of concizumab to both on-demand and prophylaxis patients
ConcizumabConcizumabDaily administration of concizumab to both on-demand and prophylaxis patients
Primary Outcome Measures
NameTimeMethod
The Number of Bleeding Episodes During at Least 24 Weeks From Treatment OnsetDuring at least 24 weeks from treatment onset

The number of bleeding episodes that were treated during at least 24 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

Secondary Outcome Measures
NameTimeMethod
Number of Treatment-emergent Adverse Events (TEAEs) During at Least 24 Weeks From Treatment OnsetDuring at least 24 weeks from treatment onset (week 0)

An adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily had a causal relationship with this treatment. A TEAE was defined as an event that had onset from the first exposure to treatment until the last visit in the trial. Number of TEAEs that occurred during at least 24 weeks from treatment onset (week 0) are presented. The data is presented per dose level participants were on at the time of onset of the adverse event.

Occurrence of Anti-concizumab Antibodies During at Least 24 Weeks From Treatment OnsetDuring at least 24 weeks from treatment onset (week 0)

Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset (week 0) is presented. In the reported data, 'Yes' infers number of participants who showed positive anti-concizumab antibody tests whereas 'No' infers number of participants who showed negative anti-concizumab antibody tests.

The Number of Spontaneous Bleeding Episodes During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset

Bleeds that were not linked to a specific, known action or event are called spontaneous bleeding episodes. The number of spontaneous bleeding episodes that were treated during at least 76 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

The Number of Bleeding Episodes During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset

The number of bleeding episodes that were treated during at least 76 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

Change in Fibrinogen During 24 Weeks From Treatment OnsetDuring 24 weeks from treatment onset (week 0)

Change in fibrinogen during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Fibrinogen During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

Change in fibrinogen during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in D-dimer During 24 Weeks From Treatment OnsetDuring 24 weeks from treatment onset (week 0)

Change in D-dimer during at least 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Prothrombin Fragment 1 + 2 (F1 + F2) During 24 Weeks From Treatment OnsetDuring 24 weeks from treatment onset (week 0)

Change in F1 + F2 during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Occurrence of Anti-concizumab Antibodies During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

Occurrence of anti-concizumab antibodies during at least 76 weeks from treatment onset (week 0) is presented. In the reported data, 'Yes' infers number of participants who showed positive anti-concizumab antibody tests whereas 'No' infers number of participants who showed negative anti-concizumab antibody tests.

Change in D-dimer During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

Change in D-dimer during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Activated Partial Thromboplastin Time (APTT) During 24 Weeks From Treatment OnsetDuring 24 weeks from treatment onset (week 0)

Change in APTT during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

The Number of Spontaneous Bleeding Episodes During at Least 24 Weeks From Treatment OnsetDuring at least 24 weeks from treatment onset

Bleeds that were not linked to a specific, known action or event are called spontaneous bleeding episodes. The number of spontaneous bleeding episodes that were treated during at least 24 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

Number of Treatment-emergent Adverse Events (TEAEs) During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

An adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily had a causal relationship with this treatment. A TEAE was defined as an event that had onset from the first exposure to treatment until the last visit in the trial. Number of TEAEs that occurred during at least 76 weeks from treatment onset (week 0) are presented. The data is presented per dose level participants were on at the time of onset of the adverse event.

Free Tissue Factor Pathway Inhibitor (TFPI) Concentration Value Prior to the Last Dose Administration at 24 WeeksPrior to the last dose administration at 24 weeks

Free TFPI (TFPI not bound to concizumab) concentration value prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Free Tissue Factor Pathway Inhibitor (TFPI) Concentration Value Prior to the Last Dose Administration After at Least 76 WeeksPrior to the last dose administration after at least 76 weeks

Free TFPI concentration value prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Endogenous Thrombin Potential Prior to the Last Dose Administration at 24 WeeksPrior to the last dose administration at 24 weeks

The endogenous thrombin potential (ETP), defined as the amount of thrombin which can be generated after the in vitro activation of coagulation with tissue factor as trigger and phospholipids as platelet substitute. Endogenous thrombin potential prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Thrombin Generation Velocity Index Prior to the Last Dose Administration at 24 WeeksPrior to the last dose administration at 24 weeks

Thrombin generation velocity index represents the effective rate of thrombin generation between lag time and time to peak. Thrombin generation velocity index prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Thrombin Generation Velocity Index Prior to the Last Dose Administration After at Least 76 WeeksPrior to the last dose administration after at least 76 weeks

Thrombin generation velocity index represents the effective rate of thrombin generation between lag time and time to peak. Thrombin generation velocity index prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Prothrombin Fragment 1 + 2 (F1 + F2) During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

Change in F1 + F2 during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Anti-thrombin (AT) During 24 Weeks From Treatment OnsetDuring 24 weeks from treatment onset (week 0)

Change in AT during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Anti-thrombin (AT) After at Least 76 Weeks From TreatmentDuring at least 76 weeks from treatment onset (week 0)

Change in AT after at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Concentration of Concizumab Prior to the Last Dose Administration at 24 WeeksPrior to the last dose administration at 24 weeks

Concentration of concizumab prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Concentration of Concizumab Prior to the Last Dose Administration After at Least 76 WeeksPrior to the last dose administration after at least 76 weeks

Concentration of concizumab prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Peak Thrombin Generation Prior to the Last Dose Administration at 24 WeeksPrior to the last dose administration at 24 weeks

Peak thrombin generation is the maximal concentration of thrombin formed at a given point in time. Peak thrombin generation prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Peak Thrombin Generation Prior to the Last Dose Administration After at Least 76 WeeksPrior to the last dose administration after at least 76 weeks

Peak thrombin generation is the maximal concentration of thrombin formed at a given point in time. Peak thrombin generation prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Prothrombin Time (PT) During 24 Weeks From Treatment OnsetDuring 24 weeks from treatment onset (week 0)

Change in PT during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Prothrombin Time (PT) During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

Change in PT during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Change in Activated Partial Thromboplastin Time (APTT) During at Least 76 Weeks From Treatment OnsetDuring at least 76 weeks from treatment onset (week 0)

Change in APTT during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Endogenous Thrombin Potential Prior to the Last Dose Administration After at Least 76 WeeksPrior to the last dose administration after at least 76 weeks

The endogenous thrombin potential (ETP), defined as the amount of thrombin which can be generated after the in vitro activation of coagulation with tissue factor as trigger and phospholipids as platelet substitute. Endogenous thrombin potential prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Trial Locations

Locations (1)

Novo Nordisk Investigational Site

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath